Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions
HemodialysisPeritoneal Dialysis
Interventions
DRUG

HEC53856

"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."

Trial Locations (7)

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

Unknown

Sichuan Provincial People's Hospital, Chengdu

The First Affiliated Hospital of Shantou University Medical College, Shantou

The First Hospital of China Medical University, Shenyang

General Hospital of Tianjin Medical University, Tianjin

Affiliated Hospital of Guangdong Medical University, Zhanjiang

The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai

All Listed Sponsors
collaborator

Nicoya Therapeutics (Shanghai) Co., Ltd.

UNKNOWN

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04925674 - Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. | Biotech Hunter | Biotech Hunter